Control of protein glycosylation by culture medium supplementation and cell culture process parameters

Patent metadata

Field	Value
Publication number	US-9944968-B2
Application number	US-201615000522-A
Country	US
Kind code	B2
Filing date	Jan 19, 2016
Priority date	Aug 19, 2013
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

First claim

What is claimed is:

1. A method of altering the glycosylation pattern of a recombinant glycoprotein produced in cell culture comprising:
culturing eukaryotic cells engineered to express a recombinant glycoprotein of interest in a cell culture medium, wherein the cell culture medium is supplemented with an additive comprising mycophenolic acid acyl glucuronide;
wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered relative to the same recombinant glycoprotein produced by the same cells in the same cell culture medium without the additive.

2. The method of claim 1 , wherein the glycosylation pattern of the recombinant glycoprotein of interest is altered to better resemble the glycosylation pattern of a reference sample of the glycoprotein.

3. The method of claim 1 , further comprising recovering the recombinant glycoprotein of interest from the cell culture.

4. The method of claim 1 , wherein the alteration of the glycosylation pattern of the recombinant glycoprotein of interest comprises one or more of a reduced level of afucosylation, a reduced level of galactosylation, a reduced level of galactose-alpha-1,3-galactose (α-gal), a reduced level of N-glycolylneuraminic acid (NGNA), and/or results in reduced FcyRIIIa binding, reduced antibody-dependent cell-mediated cytotoxicity.

5. The method of claim 1 , wherein the alteration of the glycosylation pattern is achieved without increasing the level of α-gal.

6. The method of claim 1 , wherein the alteration of the glycosylation pattern is achieved without reducing sialic acid levels.

7. The method of claim 1 , wherein the alteration of the glycosylation pattern is achieved while maintaining culture density, cell viability, or both culture density and cell viability.

8. The method of claim 1 , wherein the cell culture comprises a growth phase and a protein production phase, and wherein the additive is introduced into the culture medium before or at the same time as the initiation of the protein production phase.

9. The method of claim 1 , wherein the cell culture is conducted in a shake flask.

10. The method of claim 1 , wherein the cell culture is conducted in a stirred-tank bioreactor.

11. The method of claim 10 , wherein the bioreactor has a volume of between about 500 liters and about 30,000 liters.

12. The method of claim 1 , wherein the supplemented cell culture medium comprises between 1 μM and 50 μM mycophenolic acid acyl glucuronide.

13. The method of claim 12 , wherein the mycophenolic acid acyl glucuronide is introduced into the cell culture medium as part of a feed medium.

14. The method of claim 12 , wherein the mycophenolic acid acyl glucuronide is introduced into the cell culture medium as one or more boli from a distinct stock solution.

15. The method of claim 1 , wherein the eukaryotic cells engineered to express a recombinant glycoprotein of interest are selected from the group consisting of CHO cells, HEK cells, NSO cells, PER.C6 cells, 293 cells, HeLa cells, and MDCK cells.

16. The method of claim 1 , wherein the eukaryotic cells engineered to express a recombinant glycoprotein of interest are hybridoma cells.

17. The method of claim 1 , wherein the eukaryotic cells engineered to express a recombinant glycoprotein of interest have been adapted to grow in serum free medium, animal protein free medium or chemically defined medium.

18. The method of claim 1 , wherein the recombinant glycoprotein of interest comprises at least a portion of: an antibody, an immunoadhesin, a Transforming Growth Factor (TGF) beta superfamily signaling molecule, a blood clotting factor, antibody against TNFR, antibody against growth factor receptors (HER2), TNFR:Fc, combinations thereof, or fragments thereof.

19. The method of claim 1 , wherein the recombinant glycoprotein of interest comprises at least one selected from the group consisting of: an antibody Fe region, an antigen-binding domain of an antibody, a full antibody, chimeric antibody, humanized antibody or human antibody, or a human IgG1 antibody.

20. The method of claim 18 , wherein the immunoadhesin comprises a tumor necrosis factor receptor.

21. The method of claim 1 , wherein the total amount of recombinant glycoprotein produced in the additive-supplemented cell culture medium is equal to the total amount of recombinant glycoprotein produced by the corresponding unsupplemented cell culture medium.

22. The method of claim 1 , wherein the total amount of recombinant glycoprotein produced in the additive-supplemented cell culture medium is decreased by less than 5%, less than 10%, less than 15%, or less than 20% of the total amount of recombinant glycoprotein produced by the corresponding unsupplemented cell culture medium.

23. The method of claim 1 , wherein the specific productivity of the engineered eukaryotic cells maintained in the additive-supplemented cell culture medium is equal to the specific productivity of the same cells maintained in the corresponding unsupplemented cell culture medium.

24. The method of claim 1 , wherein the cell culture is a perfusion culture or a fed batch culture.

25. The method of claim 1 , wherein the method further comprises controlling or modulating cell culture temperature.

26. The method of claim 25 , wherein the cell culture temperature is about 25 to about 42° C.

27. The method of claim 25 , wherein the mycophenolic acid acyl glucuronide is introduced at the same time as the cell culture temperature is controlled or modulated.

28. The method of claim 1 , wherein the method further comprises controlling or modulating cell culture seed density.

29. The method of claim 28 , wherein the cell culture seed density is higher than 5.5×10 5 vc/mL.

30. The method of claim 1 , wherein the alteration of the glycosylation pattern of the recombinant glycoprotein of interest comprises one or more of an increased N-glycan charge, or increased level of afucosylation.

31. The method of claim 28 , wherein the cell culture seed density is lower than 3.5×10 5 vc/mL.

Assignees

• Biogen Ma Inc
• Samsung Bioepis

Inventors

• Yang William
• Huang Yao-Ming
• Mcelearney Kyle
• Tescione Lia
• Lambropoulos James
• Zhang An
• Tsang Valerie
• Ryll Thomas
• Lee Sangil
• Lee Dae Sung

Classifications

• C12N2500/40

  Nucleotides, nucleosides or bases · CPC title

• C12N2501/04

  Immunosuppressors, e.g. cyclosporin, tacrolimus · CPC title

• C12N2511/00

  Cells for large scale production · CPC title

• C12N2500/20

  Transition metals · CPC title

• C12N5/0018

  Culture media for cell or tissue culture (media for specific animal cell type C12N5/06) · CPC title